BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuroda N, Toi M, Hiroi M, Enzan H. Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 2003;18:551-5. [PMID: 12647806 DOI: 10.14670/HH-18.551] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
Number Citing Articles
1 Liu XH, Zou QM, Cao JD, Wang ZC. Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report . World J Clin Cases 2022; 10(32): 11942-11948 [DOI: 10.12998/wjcc.v10.i32.11942] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
3 Boustany J, Abdessater M, Hachem CE, Khoury ZE, Khoury WE, Khoury RE. Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib. Oncotarget 2020;11:1922-8. [PMID: 32499875 DOI: 10.18632/oncotarget.27543] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol 2019;37:115-23. [PMID: 29858701 DOI: 10.1007/s00345-018-2355-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
5 Hsieh CH, Hsiung SC, Yeh CT, Yen CF, Chou YW, Lei WY, Pang ST, Chuang CK, Liao SK. Differential expression of CD44 and CD24 markers discriminates the epitheliod from the fibroblastoid subset in a sarcomatoid renal carcinoma cell line: evidence suggesting the existence of cancer stem cells in both subsets as studied with sorted cells. Oncotarget 2017;8:15593-609. [PMID: 28121626 DOI: 10.18632/oncotarget.14777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
6 Wei S, Al-Saleem T. The Pathology and Molecular Genetics of Sarcomatoid Renal Cell Carcinoma: A Mini-Review. J Kidney Cancer VHL 2017;4:19-23. [PMID: 28725540 DOI: 10.15586/jkcvhl.2017.70] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
7 Miolo G, Ash A, Buonadonna A, Lo Re G, Torrisi E, Cervo S, Santeufemia DA, Tuzi A, Canzonieri V. Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. Cancer Biol Ther 2014;15:1439-43. [PMID: 25482943 DOI: 10.4161/15384047.2014.956642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Bukelo MM, U S, Rai S. Sarcomatoid renal cell carcinoma: case report and review of literature. J Clin Diagn Res 2014;8:FD01-2. [PMID: 25177568 DOI: 10.7860/JCDR/2014/8904.4539] [Reference Citation Analysis]
9 Pal SK, Jones JO, Carmichael C, Saikia J, Hsu J, Liu X, Figlin RA, Twardowski P, Lau C. Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis. Urol Oncol 2013;31:1826-31. [PMID: 22608544 DOI: 10.1016/j.urolonc.2012.04.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
10 Hager M, Haufe H, Kemmerling R, Hitzl W, Mikuz G, Moser PL, Kolbitsch C. Increased activated Akt expression in renal cell carcinomas and prognosis. J Cell Mol Med 2009;13:2181-8. [PMID: 18774962 DOI: 10.1111/j.1582-4934.2008.00488.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
11 Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 2010;9:1525-35. [PMID: 20501804 DOI: 10.1158/1535-7163.MCT-09-1106] [Cited by in Crossref: 135] [Cited by in F6Publishing: 145] [Article Influence: 10.4] [Reference Citation Analysis]
12 Hsieh CH, Hsu YJ, Chang CC, Liu HC, Chuang KL, Chuang CK, Pang ST, Hasumi K, Ferrone S, Liao SK. Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes. Cancer Immunol Immunother 2009;58:395-408. [PMID: 18704411 DOI: 10.1007/s00262-008-0565-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]